WORLD JOURNAL OF PHARMACEUTICAL RESEARCH
Coden USA: WJPRAP Impact Factor 8.63
Volume 15, Issue 11, 146-168. Review Article ISSN 2277–7105

ROLE OF NEUROINFLAMMATION IN DEPRESSION AND ANTIDEPRESSANT DRUG DEVELOPMENT: EMERGING INSIGHTS AND THERAPEUTIC PERSPECTIVES

Mr. Suraj S. Chilkawar*, Dhananjay R. Tidke, Dr. Dinesh R. Chaple, Ayush V. Umare, Sumit S. Raut, Deepak S. Dodke

Department of Pharmaceutical Chemistry, Priyadarshini J.L. College of Pharmacy, Electronic Zone Building, MIDC Hingna Road, Nagpur, Maharashtra, India.

Article Received on 25 April 2026,
Article Revised on 15 May 2026,
Article Published on 01 June 2026,

https://doi.org/10.5281/zenodo.20438494

***Corresponding Author**

Mr. Suraj S. Chilkawar

Department of Pharmaceutical Chemistry, Priyadarshini J.L. College of Pharmacy, Electronic, Zone Building, MIDC Hingna Road, Nagpur, Maharashtra, India.

How to cite this Article: Mr. Suraj S. Chilkawar*, Dhananjay R. Tidke, Dr. Dinesh R. Chaple, Ayush V. Umare, Sumit S. Raut, Deepak S. Dodke. (2026). Role of Neuroinflammation In Depression and Antidepressant Drug Development: Emerging Insights And Therapeutic Perspectives. World Journal of Pharmaceutical Research, 15(11), 146–168.

ABSTRACT

As a result of several triggers, depression is a multifactorial psychiatric disorder characterized by constant sadness, anhedonia, and disturbances in cognitive processes. Millions of people worldwide experience this mental illness, with traditional antidepressants targeting mainly monoaminergic mechanisms. Despite this, a considerable number of patients show inadequate responsiveness to existing treatments. Recent studies suggest a connection between depression development and neuroinflammation, with activation of microglia and astrocyte cells along with elevated levels of pro-inflammatory cytokines, such as IL-6, TNF-α, and IL-1β, affecting neurotransmission, neurogenesis, and HPA dysfunction. This review explores the role of neuroinflammation in depression mechanisms and possible applications in developing novel antidepressants. Specific focus will be paid to the most prominent pathways involved in neuroinflammation – pro-inflammatory cytokines, oxidative stress, and immune imbalance. The article reviews their relationship with neurotransmission mechanisms and provides insights into potential antidepressant therapies involving the reduction of inflammation. The discovery of neuroinflammation involvement in depression paves the way for designing a new generation of antidepressants. Based on immunology, neurobiology, and

pharmacology, future studies may help in creating effective and fast-acting drugs for treating depression.

KEYWORDS: Antidepressants, Astrocytes, Cytokines, Depression, HPA axis, IL-1β, IL-6, Immune system, Inflammation, Microglia, Neurogenesis, Neuroinflammation, Neuroplasticity, NMDA receptor, Oxidative stress, SSRIs, TNF-α, Tryptophan metabolism, Kynurenine pathway, Therapeutic targets.

1. INTRODUCTION

Major depressive disorder (MDD) is an extremely complex and heterogeneous mental disorder that entails prolonged sadness, anhedonia, cognitive deficits, as well as disrupted sleeping and eating patterns. MDD is one of the main contributors to disability on the planet and contributes considerably to the disease burden across the globe. Despite abundant scientific investigations and a wide variety of medications, including SSRIs, SNRIs, and TCAs, only a portion of patients achieve full recovery, suggesting the importance of investigating the etiology of MDD.[1,2]

Monoaminergic deficiency was traditionally considered the key pathophysiological factor underlying MDD, implying that the condition results from insufficient levels of serotonin, norepinephrine, and dopamine. However, this theory fails to explain the delayed therapeutic effects of antidepressants as well as the unresponsiveness to pharmacological intervention of up to one-third of patients.[3] Hence, alternative models have been proposed, with neuroinflammation gaining popularity recently.

Neuroinflammation is an activation of the brain's innate immune system, with microglia and astrocytes as key participants. During the activation process, numerous pro-inflammatory cytokines, chemokines, and various inflammatory mediators are secreted. According to the results of recent studies, patients diagnosed with depression exhibit increased levels of inflammation markers such as IL-6, TNF-α, and IL-1β, both in peripheral circulation and cerebrospinal fluid.[4,5] Inflammatory mediators can influence neurotransmitter metabolism, affect the processes of synaptic plasticity, and influence neuroendocrine activity.[6]

It should be noted that one of the central mechanisms linking inflammation and depression includes the enzyme indoleamine 2,3-dioxygenase (IDO), which redirects the metabolism of tryptophan and reduces the level of serotonin synthesis. Inflammation increases the level of

kynurenine metabolites that may cause additional neurotoxicity and deterioration of mood state.[7] Additionally, chronic inflammation is associated with the inhibition of neurogenesis and decreased levels of BDNF.

The microglia play a crucial role in neuroinflammation. In case of prolonged stress exposure, these cells switch their state to an inflammatory phenotype characterized by the release of cytokines and reactive oxygen species, causing neuronal injury and synaptic malfunction. Thus, inflammation creates an endless cycle by disturbing neurotransmitter function and neural circuits controlling emotions. Moreover, immunological stimuli generated in other parts of the body may enter the brain or induce neural pathways, thus amplifying neuroinflammation.[9]

Recently, the relationship between neuroinflammation and depressive disorder has been conceptualized as bidirectional. While the processes of inflammation can trigger depression, the psychological stress and environmental triggers may also influence the neuroinflammatory response. Therefore, the new perspective views neuroinflammation as an innovative target for antidepressant therapy. Scientists examine various strategies involving anti-inflammatory compounds, cytokine antagonists, and microglial activators as novel antidepressants.[10]

The purpose of this review is to comprehensively investigate the role that neuroinflammation plays in the pathology of depression. In doing so, by collating data obtained at the molecular, cellular, and clinical levels, it seeks to provide new insights into treatment strategies for this condition.



Figure 1: Illustrates the role of neuroinflammation in depression, including microglial activation, cytokine release (IL-6, TNF-α, IL-1β), activation of the kynurenine pathway, neurotransmitter imbalance, and impaired neurogenesis.

2. PATHOPHYSIOLOGY OF NEUROINFLAMMATION IN DEPRESSION

Neuroinflammation can be seen as the complex interplay between the nervous system and immunity. The first stage consists of activation of glial cells and a cascade of inflammatory mediators, which eventually affect neuronal function and synaptic plasticity. Indeed, a body of literature highlights the significance of chronic inflammation in the pathogenesis of depression by various pathways.[11,12]

2.1 Microglial Activation and Polarization

Microglia are considered the immune cells of the CNS that play a vital role in maintaining neuronal homeostasis. Under physiological conditions, they remain quiescent; however, upon exposure to continuous stress, infection, and injury, they become activated and polarize into two primary phenotypes, namely M1 and M2.[13] The M1 phenotype produces cytokines with pro-inflammatory actions, such as IL-1β, IL-6, and TNF-α. Additionally, it produces ROS and NO. Both of these factors can negatively impact neuronal functioning, synaptic transmission, and neuroplasticity. The M2 phenotype is associated with processes such as tissue healing, anti-inflammatory reactions, and neuroprotection.[14]

There is a persistent activation of M1 phenotype in microglia under depressive disorders, leading to sustained neuroinflammation and neuronal impairment.[15]

2.2 Pro-inflammatory Cytokines and Neurotransmitter Dysfunction

The presence of increased pro-inflammatory cytokines is characteristic of depression. These include IL-1β, IL-6, and TNF-α. The impact of such factors is mediated by changes in the production, release, and uptake of neurotransmitters.[16] By inducing the expression of IDO, these agents promote serotonin depletion and guide tryptophan toward the kynurenine pathway.[17]

On the other hand, pro-inflammatory cytokines affect dopamine transmission and glutamate metabolism, resulting in overactivity and neuronal dysfunction. Moreover, the processes of synaptic plasticity are hindered by these agents, along with decreased BDNF synthesis.[18]

2.3 Dysregulation of the HPA Axis

The HPA axis (hypothalamic-pituitary-adrenal) is central in our reaction to stress. If stress continues, then the HPA axis keeps working, as does the cortisol, which eventually, due to prolonged secretion, weakens the functioning of the hippocampus, reduces neurogenesis, and

increases the activity of inflammation.[19]

Additionally, the inflammatory cytokine activates the HPA axis, creating an inflammatory cycle that maintains stress. Inflammation and stress influence one another; their interaction contributes to the development of depression.[20]

2.4 Kynurenine Pathway Activation

One of the most critical links between inflammation and depression is the activation of the kynurenine pathway. The stimulation of IDO in response to inflammation promotes the conversion of tryptophan to kynurenine instead of serotonin. The metabolism of kynurenine produces neurotransmitters such as quinolinic acid (neurotoxic) and kynurenic acid (neuroprotective). If neurotoxic metabolites predominate, they stimulate excessive glutamate excitotoxicity.[21]



Figure 2: Neuroinflammation-mediated activation of the kynurenine pathway and its role in depression.

2.5 Blood–Brain Barrier (BBB) Dysfunction

The blood-brain barrier (BBB) plays an essential role in the maintenance of homeostasis in the brain's microenvironment by regulating access of substances from the peripheral part of the body to the central nervous system (CNS). In cases when there is an increase in inflammatory activity, the blood-brain barrier becomes less effective, allowing the passage of

cytokines and immune cells to the brain tissue.[22]

The leakage facilitates neuroinflammation and forms a connection between systemic and neuroinflammatory processes. Alterations in the BBB have been reported among individuals suffering from major depressive disorder, and it is considered one of the critical factors of the disorder's progression.[23]

2.6 Oxidative Stress and Mitochondrial Dysfunction

Increased neuroinflammation is usually associated with increased oxidative stress due to excessive ROS production. ROS have the ability to damage lipids, proteins, and DNA molecules, leading to neuronal dysfunction and initiating apoptosis.[24]

In case of impaired mitochondrial function, oxidative stress increases due to impaired cell energy metabolism. Mitochondrial dysfunction is responsible for producing synaptosomal deficits and decreased neuroplasticity associated with depression.[25]

Table 1: Key Mechanisms of Neuroinflammation in Depression.

Mechanism	Key Features	Impact on Depression
Microglial activation	M1 polarization, cytokine release	Neuronal damage, synaptic dysfunction
Cytokine signaling	IL-1β, IL-6, TNF-α	Neurotransmitter imbalance
HPA axis dysregulation	Cortisol elevation	Impaired neurogenesis
Kynurenine pathway	IDO activation	Reduced serotonin, neurotoxicity
BBB dysfunction	Increased permeability	Peripheral immune infiltration
Oxidative stress	ROS production	Neuronal damage

3. MOLECULAR MECHANISMS LINKING NEUROINFLAMMATION AND DEPRESSION

Neuroinflammation impacts depression through multiple pathways involving neurochemical changes in neurotransmission, synaptic plasticity, and neuronal survival. All these aspects are highly interconnected, resulting in the formation of complex communication pathways between the immune system and brain mechanisms. Understanding all these pathways is important to determine novel targets for antidepressants.[26,27]

3.1 Neurotransmitter Dysregulation

Indeed, neuroinflammation usually alters the brain's chemistry, with neurotransmitters involved in serotonin metabolism, as well as in dopamine and glutamate synthesis being impacted. Upon entering the stage, inflammatory cytokines such as IL-1β, IL-6, and TNF-α

induce IDO activation and redirect tryptophan from serotonin synthesis to the kynurenine pathway. As a consequence of this change, serotonin levels drop significantly, which directly correlates with depression.[28]

In addition, inflammation negatively influences dopamine functioning as well, decreasing its production and release; that contributes to such clinical features as loss of interest and reduced energy and motivation seen in patients suffering from depression.[29] Furthermore, inflammation also impacts glutamate through decreased expression of glutamate transporters, leading to increased extracellular glutamate accumulation.[30]

3.2 Glutamate Excitotoxicity and NMDA Receptor Activation

The effects of neuroinflammation have an adverse effect on glutamatergic neurotransmission. This occurs through the accumulation of a compound called quinolinic acid from the kynurenine pathway, which amplifies NMDA receptors to release high levels of calcium inside neurons, leading to their dysfunction.[31]

Simultaneously, inflammatory cytokines reduce the efficiency of astrocytes in absorbing glutamate, keeping the concentrations of the neurotransmitter in extracellular fluid elevated. Excitotoxicity is the result, impairing synapse functioning and damaging neurons in brain regions involved in mood control.[32]



Figure 3: Neuroinflammation-induced alterations in glutamatergic neurotransmission and synaptic plasticity in depression.

3.3 Impaired Neuroplasticity and BDNF Signaling

BDNF contributes significantly to the development, maintenance, and plasticity of the neurons. Under inflammation, there tends to be a reduced amount of BDNF in the brain, and this has adverse effects on neuroplasticity. It further leads to the structural and functional alterations that characterize depression.[33]

The inflammatory cytokines affect the signaling pathways of BDNF by inhibiting the signaling through the TrkB receptor pathway. The reduction in BDNF causes an increase in synaptic connectivity as well as neurogenesis in the hippocampus, leading to cognitive dysfunction.[34]

3.4 Immune-to-Brain Communication Pathways

Peripheral immune activation can influence brain function through multiple communication routes:

- **Humoral pathway:** Cytokines cross the blood–brain barrier (BBB) through active transport mechanisms
- **Neural pathway:** Activation of the afferent vagus nerve signaling
- **Cellular pathway:** Migration of immune cells into the CNS

  These pathways allow systemic inflammation to directly affect central nervous system function and contribute to depressive symptoms.[35]

3.5 Interaction Between Neuroinflammation and Neuroendocrine System

The neuroinflammatory processes and the neuroendocrine system, particularly the HPA axis, are highly interconnected. The cytokine activates the secretion of CRH, which increases the production of cortisol.[36] Elevated levels of cortisol for an extended period lead to the intensification of inflammation, thereby creating a vicious circle that perpetuates stress and neuroinflammation. This two-sided interaction explains the genesis of depression.[37]

3.6 Epigenetic Modifications and Gene Expression

New studies have shown that neuroinflammation can cause epigenetic modifications resulting in changes in the expression of genes responsible for the regulation of mood. Such mechanisms include DNA methylation, histone modification, and miRNA regulation.[38]

Inflammatory mediators such as pro-inflammatory cytokines have been found to affect gene activity associated with neurotransmission, neuroplasticity, and physiological stress response.

These changes might be the reason behind recurrent depression and variability in treatment responses.[39]

Table 2: Molecular Mechanisms Linking Neuroinflammation and Depression.

Mechanism	Molecular Target	Outcome
Serotonin depletion	IDO activation	Reduced mood regulation
Dopamine dysfunction	Reduced synthesis/release	Anhedonia
Glutamate excitotoxicity	NMDA receptor activation	Neuronal damage
Reduced BDNF	TrkB signaling inhibition	Impaired neuroplasticity
Immune-brain signaling	Cytokine pathways	CNS inflammation
Epigenetic changes	DNA methylation, miRNA	Long-term alterations

4. ANTIDEPRESSANT DRUG DEVELOPMENT TARGETING NEUROINFLAMMATION

The increasing recognition of the involvement of neuroinflammation in depression has led to a shift in the development of antidepressants from conventional treatments focusing on modifying monoaminergic pathways to new therapies involving the reduction of inflammation, the modulation of glial cells' function, and the modification of immunological signaling pathways. The target of such therapy will not only be symptom management but also the resolution of the underlying pathogenesis of the disease, particularly for patients suffering from treatment-resistant depression.[40,41]

Numerous animal and human studies have reported promising results in terms of restoration of neurotransmitters, promotion of neuroplasticity, and alleviation of depressive symptoms by blocking neuroinflammatory mechanisms. They include anti-inflammatory drugs, cytokine blockers, microglia modulators, glutamatergic regulators, and natural products with immunomodulatory properties.

4.1 Anti-Inflammatory Agents and NSAIDs

NSAIDs have also been considered as adjunct therapy for depression since they inhibit the cyclooxygenase enzymes and reduce prostaglandin-induced inflammation. Clinical research has shown that NSAID medications such as Celebrex increase the efficacy of conventional antidepressants in people with high inflammatory profiles.[42]

The mechanism behind the antidepressant effect of NSAIDs includes reducing the production of pro-inflammatory cytokines and stabilizing neurotransmitter function. However, NSAIDs' use as an adjunct therapy for depression has been restricted due to potential side effects involving gastrointestinal and cardiovascular health.[43]

4.2 Cytokine Inhibitors and Immunotherapy

Aiming at specific cytokines is a more targeted method for treatment. For instance, anti-TNF-α therapies such as infliximab have been successful in those who initially have high inflammatory markers. Through suppressing inflammation in the body and brain, these medications have positive effects on mood and cognition.[44] Meanwhile, there are ongoing efforts to develop IL-6 and IL-1β inhibitors. Despite their specificity in treatment, they are relatively expensive and may cause immunosuppressive side effects.[45]

4.3 Microglial Modulators

The microglia cells are central to the process of neuroinflammation, hence making them ideal candidates for depression therapy. Minocycline, a tetracycline-based antimicrobial with anti-inflammatory properties, has been seen to reduce microglia activity by reducing the levels of pro-inflammatory cytokines.[46]

Conversion of the M1 state of microglia into the M2 state of microglia will help restore the neuron balance and improve synaptic functions. It has been proven clinically that minocycline is useful as a supplementary drug in depression treatments for people with higher inflammation levels.[47]



Figure 4: Microglial polarization and its role in neuroinflammation, neuroplasticity, and depression.

4.4 Glutamatergic Modulators and NMDA Receptor Antagonists

The emergence of a new class of drugs called rapidly acting drugs, targeting the glutamatergic system, is one of the breakthroughs in antidepressant treatment. Ketamine, a drug that acts as an antagonist of the NMDA receptors, often provides fast and intense antidepressant effects within hours after administering the dose.[48]

The mechanism of action of this drug is based on inhibiting the activity of NMDA receptors, thereby increasing synaptic plasticity through activation of the mTOR pathway and increased BDNF secretion.[49] Additionally, ketamine has anti-inflammatory properties, decreasing the activation of microglia and cytokine release.[50]

Esketamine, which belongs to ketamine, is one of the recent approvals for treating depression resistant to traditional therapy.[50]

4.5 Natural Compounds with Anti-inflammatory Properties

This has been the case since these compounds have proven to be relatively safer and have multi-target effects on cells. Curcumin, resveratrol, and a number of flavonoids are among the natural substances that exhibit high potency against inflammation and antioxidants.[51]

Curcumin, for instance, has been observed to inhibit the activity of NF-κB pathways, decrease cytokine production, while enhancing BDNF concentrations and neurogenesis. The same is true about resveratrol, which modulates inflammatory responses as well as enhances mitochondrial functions.[52]

These compounds hold much potential as adjuncts or substitutes in antidepressant treatment.

Table 3: Therapeutic Strategies Targeting Neuroinflammation in Depression.

Drug/Class	Target	Mechanism	Clinical Status
NSAIDs (Celecoxib)	COX enzymes	Reduce prostaglandins	Adjunct therapy
TNF-α inhibitors	Cytokines	Block inflammatory signaling	Clinical trials
Minocycline	Microglia	Inhibits activation	Adjunct therapy
Ketamine/Esketamine	NMDA receptor	↑ BDNF, synaptic plasticity	Approved
Curcumin	NF-κB pathway	Anti-inflammatory	Experimental
Resveratrol	Oxidative stress	Antioxidant	Experimental



Figure 5: Neuroinflammation-driven alterations in monoamine and glutamate metabolism and their impact on neural circuits in depression.

5. EXPERIMENTAL MODELS USED TO STUDY ANTIDEPRESSANT ACTIVITY

In analyzing the influence of antidepressants when neuroinflammation plays an important role, the combination of behavioral analysis, biochemistry, and molecular aspects proves essential. Such experimentation is essential for gaining a greater understanding of pathogenesis, testing novel compounds, and identifying target molecules. Scientists usually perform experiments on living animal subjects and in vitro cells to induce depressive-like behavior in the presence of inflammation.[53,54]

Animal models of depression try to mimic specific symptoms experienced by humans, including depression and difficulties with cognition. Simultaneously, biochemical analysis evaluates inflammation, oxidative damage, and alterations in the levels of neurotransmitters.

5.1.1 Forced Swim Test (FST)

The forced swim test is considered to be the most prevalent method used to evaluate the activity of antidepressants. According to this method, animals are placed in a container filled with water and carefully observed. Immobility in this test is considered an indicator of behavioral despair, while a decrease in immobility is regarded as a sign of antidepressant activity.[55]

This technique proves to be highly useful for studying drugs affecting monaminergic and inflammatory systems; however, it mostly evaluates short-term effects and might fail to cover the features of chronic disorders.

5.1.2 Tail Suspension Test (TST)

The tail suspension test is one of the most common behavioral tests, particularly with rodents. This test involves suspending the subjects from the tip of the tail, and the duration of their immobility is noted. Just like the FST, shorter immobility durations indicate an antidepressant effect.[56] However, this test is easy to conduct, fast, and very sensitive to drugs. On the other hand, just like the FST, this test also poses similar limitations, such as not applying to human chronic depression.

5.1.3 Chronic Unpredictable Mild Stress (CUMS) Model

Chronic mild stress (CMS) is one of the most reliable methodologies that mimics human depression. In the CMS model, experimental animals are exposed to a variety of unpredictable and mildly stressful stimuli over a period of weeks, leading to changes in behavior such as anhedonia, measured using the sucrose preference test.[57] Contrary to short-term acute animal models, CMS mimics the long-term duration of depression and hence offers greater value when investigating inflammation and therapeutic effects.

5.2 Biochemical and Molecular Assessments

Apart from behavioral experiments, biochemical studies play an important role in evaluating neuroinflammatory processes and the effects of antidepressants. These include:

- Cytokine profiling (IL-1β, IL-6, TNF-α)

- Oxidative stress assessment (ROS, MDA, SOD)
- Neurotransmitter measurement (serotonin, dopamine)
- BDNF expression evaluation

These methods help to reveal the mechanisms through which pharmacological interventions affect inflammation and neuronal processes.[58]

5.3 In Vitro Models of Neuroinflammation

Cellular models are the go-to choice for investigating neuroinflammation at the molecular level. Microglia cell lines like BV2 cells are used along with LPS to induce inflammation.[59] Such models provide the means to evaluate the effects of drugs on inflammation via measurement of cytokines, altered gene expression, and activation of signaling pathways. Furthermore, astrocytes and neurons are cultured to study the specific effect of inflammatory stimuli on different cell types.

5.4 Translational and Clinical Relevance

Despite the fact that both the cellular and animal models provide useful information, making use of these findings to develop antidepressant drugs is rather complicated due to several reasons, including differences between human physiology and behavior, as well as the environment. Thus, both experimental and clinical data must be integrated for the creation of efficient antidepressants.[60]

Table 4: Experimental Models for Antidepressant Activity.

Model	Type	Key Feature	Relevance
Forced Swim Test	In vivo	Immobility behavior	Acute screening
Tail Suspension Test	In vivo	Behavioral despair	Rapid screening
CMS Model	In vivo	Chronic stress exposure	High translational value
LPS-induced model	In vivo/in vitro	Inflammation induction	Mechanistic studies
Cell culture (BV2)	In vitro	Cytokine production	Molecular analysis



Figure 6: Summarizes experimental models used in antidepressant research, including behavioral, biochemical, and cellular approaches.

6. NATURAL COMPOUNDS WITH ANTIDEPRESSANT AND ANTI-INFLAMMATORY ACTIVITY

Recent studies on natural product extracts have highlighted their therapeutic potential for depression due to their ability to affect multiple biological mechanisms. In contrast to regular antidepressants which primarily affect monoamine neurotransmitters, natural substances can act through various means, namely anti-inflammatory, antioxidant, and neuroprotective activities, and may even induce neurogenesis. These combined properties make natural compounds particularly useful for treating depression with complicated pathology including cases associated with neuroinflammation.[61,62]

Increasing amounts of pre-clinical and clinical evidence have shown that plant chemicals such as polyphenols, flavonoids, and alkaloids are capable of regulating inflammatory mediators, decreasing oxidative burden, and enhancing neuroplasticity. In addition, most of these substances are characterized by good safety, allowing them to be administered chronically and in combination with other therapies.

6.1 Curcumin

The polyphenolic compound extracted from the plant Curcuma longa known as curcumin is one of the extensively studied bioactive compounds in relation to mood disorders and inflammation. Curcumin inhibits NF-κB, which is one of the key activators of inflammatory cytokines, including IL-6 and TNF-α.[63] In addition to its anti-inflammatory properties, curcumin enhances the production of brain-derived neurotrophic factors (BDNF), which stimulate neurogenesis and synaptic plasticity. Furthermore, curcumin influences monoaminergic neurotransmission through an increase in the levels of serotonin and dopamine.[64]



Figure 7: illustrates the mechanisms of curcumin in depression, including inhibition of NF-κB signaling, reduction of cytokine production, and enhancement of BDNF-mediated neuroplasticity.

6.2 Resveratrol

Resveratrol is a phytochemical that can be found in grapes, berries, and peanuts. Resveratrol possesses powerful antioxidant and anti-inflammatory properties and has been found to affect various pathways that have been associated with the development of depression.[65] Resveratrol reduces neuroinflammation by reducing pro-inflammatory cytokine levels and inhibiting the activation of microglia. Resveratrol is known to stimulate the activity of mitochondria and reduce oxidative stress, resulting in increased neuronal survival. Moreover, resveratrol is known to activate the SIRT1 signaling pathway.[66]

6.3 Flavonoids

Flavonoids constitute a wide-ranging class of phytochemicals that occur ubiquitously in nature, being present in both fruits and vegetables and medicinal plants. Prominent flavonoids include quercetin, kaempferol, and apigenin. The antidepressant activity of flavonoids is mainly attributed to their anti-inflammatory and antioxidant properties.[67] Flavonoids reduce the synthesis of pro-inflammatory cytokines, prevent oxidative stress, and increase BDNF levels. Furthermore, flavonoids affect the neurotransmitter systems, especially the serotonergic and dopaminergic pathways.[68]

6.4 Other Promising Natural Compounds

Besides curcumin and resveratrol, several other natural substances may be considered for their antidepressant efficacy:

- Ginsenosides derived from Panax ginseng, with their anti-inflammatory and neuroprotective benefits
- Omega-3 fatty acids, known for reducing cytokines and enhancing neuronal membrane activity
- Alkaloids, effective in influencing neurotransmitter systems

All these provide ample evidence that natural substances have great therapeutic potential for dealing with neuroinflammation and depression.[69]

Table 5: Natural Compounds with Antidepressant Activity.

Compound	Source	Mechanism	Effect
Curcumin	Turmeric	NF-κB inhibition, ↑ BDNF	Anti-inflammatory, neurogenic
Resveratrol	Grapes	SIRT1 activation, antioxidant	Neuroprotective
Flavonoids	Fruits/vegetables	Cytokine inhibition	Antidepressant
Ginsenosides	Ginseng	Neuroprotection	Mood enhancement
Omega-3	Fish oils	Anti-inflammatory	Cognitive improvement

7. FUTURE PERSPECTIVES AND EMERGING TRENDS

The understanding that neuroinflammation is an important cause of depression opens up new avenues for investigation and treatment. However, although there has been significant progress, translating the knowledge to practical and effective therapies poses challenges that persist. Future research needs to integrate developments from immunology, neuroscience, and precision medicine to formulate tailored therapies.[70,71]

7.1 Personalized Medicine and Biomarker-Based Therapy

One of the most exciting avenues to explore in the field of depression medications is that of personalized medicine. Depression can be very heterogeneous, and not all individuals exhibit increased inflammation. Therefore, testing for biomarkers associated with inflammation, including increased cytokine concentrations, like IL-6, TNF-α, and CRP, could help determine whether individuals may benefit from anti-inflammatory medication.[72]

The use of personalized medicine means targeting an individual's unique biological signature, and it could enhance treatment response while avoiding exposing patients unnecessarily to certain medications. Several recent studies show that those with high inflammation respond much better to cytokine-targeting drugs rather than regular antidepressants.[73]

7.2 Advances in Neuroimaging and Molecular Diagnostics

The recent development of brain imaging techniques and molecular profiling is opening up the possibility of observing neuroinflammation occurring in vivo. Imaging technologies such as PET and fMRI can enable monitoring of microglial functioning, mapping of connections among different networks in the brain, and tracking the changes associated with depression.[74]

In terms of molecules, significant progress in the fields of transcriptomics, proteomics, and metabolomics helps to understand the complex relationship between immunity and nervous systems.[75]

7.3 Artificial Intelligence in Antidepressant Drug Discovery

AI and machine learning are revolutionizing drug discovery processes. These technologies accelerate target identification and assist in optimizing drug candidates rapidly. Through analyzing massive amounts of information about gene expressions, protein interactions, and

patients' outcomes, AI-driven systems reveal patterns useful for developing new antidepressants and advancing the drug discovery process.[76]

In the field of neuroinflammation, artificial intelligence can uncover the crucial central regulatory mechanisms, predict the pharmacodynamics of a drug compound and its interaction with a receptor, and develop drugs that combine efficacy and safety. All of the above-mentioned approaches show promising possibilities for dramatically reducing the time and financial resources needed to create new medications.

7.4 Challenges and Limitations

Despite this promising development, translation of neuroinflammatory-based therapies from benchtop to bedside poses multiple challenges, including:

- Heterogeneity of depression: only some patients exhibit inflammatory markers.
- Lack of biomarker standardization: measurement techniques differ.
- Risks associated with immunotherapy: adverse effects may include immune suppression.
- Complex nature of brain–immune interaction: exact pathways are hard to determine.

Furthermore, many observations made in animals or cells have not translated well into human studies due to complexities related to physiology and pathophysiology. Addressing these challenges requires advanced experimental models, standardized methodologies, and large-scale clinical trials.[77]

7.5 Integration of Multidisciplinary Approaches

Future developments in this domain will depend on integrating various branches of science, including neuroscience, immunology, pharmacology, and computational biology. The success will be achieved through joint efforts of university researchers, the biotechnology industry, and medical professionals, who should convert fundamental discoveries into medications.

Moreover, using the combination of pharmacotherapy and behavioral interventions, including diet improvement, physical activity, and relaxation exercises, could provide additional advantages in depression treatment.[78]

Table 6: Emerging Trends in Antidepressant Research.

Area	Key Advancement	Impact
Personalized medicine	Biomarker-based therapy	Improved efficacy
Neuroimaging	PET, fMRI	Mechanistic insights
AI & ML	Drug discovery	Faster development

Molecular biology	Omics technologies	Target identification
Integrative therapy	Lifestyle + drugs	Holistic treatment

8. CONCLUSION

The etiology and course of depressive disorder is complex, multilayered and remains poorly understood today, with the current nosological concept failing to provide sufficient guidance for effective pharmacotherapy. Monoaminergic concepts which were the focus of attention for drug developers during decades cannot explain the high heterogeneity of depression and its insufficiently low effectiveness of therapy.

In recent years, the idea of neuroinflammation as an important factor in depressive disorder's pathogenesis became highly popular. The concept includes a number of phenomena such as microglial activation, imbalance of cytokines, oxidative stress and alterations in neuroplasticity. These factors affect important neurotransmitter and neuroendocrine systems and cause a restructuring of brain structures responsible for emotional regulation.

Approaches based on targeting neuroinflammation have resulted in development of a new generation of anti-depressants that include anti-inflammatory drugs, cytokine antagonists, microglial regulators and glutamate agonists such as ketamine. As well as other drugs for treatment, natural substances possessing anti-inflammatory and neuroprotective effects are considered as promising adjuvants with good tolerability.

Nevertheless, there are challenges ahead. Depression is multifaceted, there is no consensus on the definition of biomarkers, and the transfer of discoveries from the laboratory setting to clinical use remains difficult. Combining personalized medicine, innovative imaging technology, molecular diagnostics, and AI could pave the way for advancements.

Overall, the emphasis on neuroinflammation is a fundamental step towards a new paradigm in antidepressant development. An understanding of the immune response and robust biomarkers are crucial for the future design of efficient, rapid, and personalized treatments.

9. REFERENCES

1. Poletti S, et al. Inflammatory mediators in major depression. *Mol Psychiatry,* 2024.
2. Zhao K, et al. Neuroinflammation and stress-induced depression. *Front Cell Neurosci,* 2025.

3. Pastis I, et al. Role of inflammation in major depressive disorder. *Front Behav Neurosci*, 2024.
4. Hussain SJ, et al. Microglial dysfunction and cytokines in depression, 2025.
5. Shi A, et al. Neuroinflammation in depression: bibliometric analysis, 2025.
6. Sălcudean A, et al. Neuroinflammation in depression mechanisms. *Biomolecules*, 2025.
7. Shi A, et al. Role of IDO and kynurenine pathway in depression, 2025.
8. Xia X, et al. Microglia and depression pathogenesis, 2025.
9. Ye X, et al. Peripheral immune system and neuroinflammation, 2025.
10. Zhao K, et al. Anti-inflammatory targets in depression, 2025.
11. Miller AH, et al. Inflammation and depression: mechanisms. *Nat Rev Immunol*, 2023.
12. Troubat R, et al. Neuroinflammation and depression. *Eur J Neurosci*, 2022.
13. Wang Y, et al. Microglial activation in depression. *Front Neurosci*, 2024.
14. Orihuela R, et al. Microglial M1/M2 polarization. *Brain Behav Immun*, 2023.
15. Yirmiya R, et al. Depression as a microglial disease. *Trends Neurosci*, 2022.
16. Dantzer R, et al. Cytokines and depression. *Nat Rev Neurosci*, 2023.
17. O'Connor JC, et al. IDO and kynurenine pathway. *J Neurosci*, 2022.
18. Castrén E, et al. BDNF in depression. *Biol Psychiatry*, 2023.
19. Pariante CM. HPA axis in depression. *Psychoneuroendocrinology*, 2022.
20. Slavich GM. Stress and inflammation. *Psychol Bull*, 2023.
21. Schwarcz R, et al. Kynurenine pathway in CNS disorders. *Nat Rev Neurosci*, 2022.
22. Varatharaj A, et al. BBB in neuroinflammation. *Lancet Neurol*, 2022.
23. Kealy J, et al. BBB dysfunction in depression. *Brain Behav Immun*, 2023.
24. Maes M, et al. Oxidative stress in depression. *Prog Neuropsychopharmacol Biol Psychiatry*, 2022.
25. Morris G, et al. Mitochondrial dysfunction in depression. *Mol Neurobiol*, 2023.
26. Felger JC, et al. Inflammation and neurotransmission. *Neuropsychopharmacology*, 2023.
27. Haroon E, et al. Immune mechanisms in depression. *Biol Psychiatry*, 2022.
28. O'Connor JC, et al. IDO activation and serotonin depletion. *J Neurosci*, 2022.
29. Felger JC. Dopamine and inflammation. *Mol Psychiatry*, 2023.
30. Haroon E, et al. Glutamate metabolism in depression. *Biol Psychiatry*, 2022.
31. Schwarcz R, et al. Quinolinic acid and NMDA receptor. *Nat Rev Neurosci*, 2022.
32. Sanacora G, et al. Glutamate hypothesis of depression. *Nat Rev Drug Discov*, 2023.
33. Castrén E, et al. BDNF and depression. *Biol Psychiatry*, 2023.
34. Duman RS, et al. Neuroplasticity in depression. *Mol Psychiatry*, 2022.

35. Dantzer R, et al. Immune-to-brain communication. *Nat Rev Neurosci*, 2023.
36. Pariante CM. HPA axis and cytokines. *Psychoneuroendocrinology*, 2022.
37. Slavich GM. Stress-inflammation feedback loop. *Psychol Bull*, 2023.
38. Nestler EJ. Epigenetics in depression. *Biol Psychiatry*, 2022.
39. Klengel T, et al. Gene-environment interaction in depression. *Nat Rev Neurosci*, 2023.
40. Miller AH, et al. Targeting inflammation in depression. *Biol Psychiatry*, 2023.
41. Khandaker GM, et al. Inflammation and antidepressant response. *Lancet Psychiatry*, 2022.
42. Köhler O, et al. Anti-inflammatory treatment in depression. *JAMA Psychiatry*, 2022.
43. Raison CL, et al. Inflammation biomarkers and treatment. *Mol Psychiatry*, 2023.
44. Raison CL, et al. TNF antagonism in depression. *Arch Gen Psychiatry*, 2022.
45. Nettis MA, et al. Cytokine inhibitors in depression. *Brain Behav Immun*, 2023.
46. Dean OM, et al. Minocycline in depression. *Aust N Z J Psychiatry*, 2022.
47. Husain MI, et al. Microglial inhibition and depression. *J Psychopharmacol*, 2023.
48. Krystal JH, et al. Ketamine mechanism. *Nat Rev Drug Discov*., 2022.
49. Duman RS, et al. Ketamine and neuroplasticity. *Science*, 2023.
50. Daly EJ, et al. Esketamine clinical use. *Am J Psychiatry*, 2022.
51. Lopresti AL. Curcumin and depression. *J Affect Disord*, 2023.
52. Berman AY, et al. Resveratrol pharmacology. *Pharmacol Res.*, 2022.
53. Willner P. Animal models of depression. *Psychopharmacology*, 2022.
54. Planchez B, et al. Experimental models of depression. *Neurosci Biobehav Rev*., 2023.
55. Porsolt RD, et al. Forced swim test method. *Nature Protocols*, 2022.
56. Steru L, et al. Tail suspension test. *Psychopharmacology*, 2022.
57. Willner P. Chronic mild stress model. *Neurobiol Stress*, 2023.
58. Maes M, et al. Biomarkers in depression. *Prog Neuropsychopharmacol*, 2022.
59. Block ML, et al. Microglial models in neuroinflammation. *Nat Rev Neurosci*, 2023.
60. Nestler EJ. Translational models in depression. *Biol Psychiatry*, 2023.
61. Lopresti AL, et al. Natural compounds in depression. *J Affect Disord*, 2023.
62. Sarris J, et al. Herbal medicines in psychiatry. *Lancet Psychiatry*, 2022.
63. Aggarwal BB, et al. Curcumin and inflammation. *Biochem Pharmacol*, 2022.
64. Kulkarni SK, et al. Curcumin in depression. *Pharmacol Biochem Behav*, 2023.
65. Berman AY, et al. Resveratrol pharmacology. *Pharmacol Res*, 2022.
66. Wang R, et al. Resveratrol and SIRT1 pathway. *Neuroscience*, 2023.
67. Panche AN, et al. Flavonoids and health benefits. *J Nutr Sci*., 2022.

68. Spencer JP. Flavonoids and brain health. *Nat Rev Neurosci*, 2023.
69. Xu Y, et al. Natural antidepressants review. *Front Pharmacol*, 2024.
70. Khandaker GM, et al. Inflammation and future therapies. *Lancet Psychiatry*, 2022.
71. Miller AH. Translational challenges in depression. *Biol Psychiatry*, 2023.
72. Felger JC. Biomarkers in depression. *Mol Psychiatry*, 2023.
73. Raison CL, et al. Inflammation-targeted treatment response. *JAMA Psychiatry*, 2022.
74. Setiawan E, et al. Neuroimaging of inflammation. *Biol Psychiatry*, 2023.
75. Geschwind DH. Omics in psychiatry. *Nature*, 2022.
76. Zhavoronkov A. AI in drug discovery. *Nat Rev Drug Discov*, 2022.
77. Nestler EJ. Challenges in depression research. *Biol Psychiatry*, 2023.
78. Sarris J, et al. Integrative psychiatry. *Lancet Psychiatry*, 2022.